Clinical Trials Browser

Phase 2/3 × Small Cell Lung Carcinoma × EC regimen × Clear all

NCT04254471 2020-02-05

This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients

Phase 2/3 Unknown

Small Cell Lung Carcinoma